A Phase 1 trial evaluating Poseida Therapeutics’ autologous CAR T-cell therapy P-PSMA-101 for metastatic castration-resistant prostate cancer (mCRPC) is resuming immediately, after its clinical hold was lifted. The U.S. Food and Drug Administration (FDA) had placed a partial hold on the trial in August, after a patient died of liver failure a few weeks after receiving the therapy. Poseida will now implement changes to its protocol to enhance patient compliance and safety, including modified criteria…
You must be logged in to read/download the full post.
The post Hold Lifted on Phase 1 Trial Testing P-PSMA-101 CAR T-cell Therapy in mCRPC appeared first on BioNewsFeeds.